Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 2

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. Jan 14, 2026; 32(2): 114057
Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.114057

Table 1 Disease activity index criteria

Citation: Zhao YQ, Zhang Y, Qin Y, Zhang RY, Wang JP. Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation. World J Gastroenterol 2026; 32(2): 114057
URL: https://www.wjgnet.com/1007-9327/full/v32/i2/114057.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i2.114057

Zhao YQ, Zhang Y, Qin Y, Zhang RY, Wang JP. Cedrol ameliorates ulcerative colitis via myeloid differentiation factor 2-mediated inflammation suppression, with barrier restoration and microbiota modulation. World J Gastroenterol 2026; 32(2): 114057 [PMID: 41551824 DOI: 10.3748/wjg.v32.i2.114057]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.